Sandoz's Tri-Lo-Estarylla estrogen and progestin combination contraceptive has been approved by the FDA. The pill, which will be distributed in 0.18 mg/0.215 mg/0.25 mg and 0.025 mg/0.025 mg/0.025 mg strengths, is therapeutically equivalent to Janssen's Ortho Tri-Cyclen Lo.
Lupin Pharmaceuticals said the FDA approved contraceptive norgestimate and ethinyl estradiol, a generic version of Janssen Pharmaceuticals' Ortho Tri-Cyclen Lo. The drug is available as a tablet at 0.25/0.025 milligrams, 0.215/0.025 milligrams and 0.18/0.025 milligrams.
Watson Laboratories and Janssen Pharmaceuticals, divisions of Watson Pharmaceuticals and Johnson & Johnson, respectively, settled a patent lawsuit involving contraceptive Ortho Tri-Cyclen Lo. The settlement allows Watson to market and distribute an authorized generic version at the end of 2015.
Ortho-McNeil-Janssen Pharmaceuticals, a unit of Johnson & Johnson, filed a lawsuit against Sandoz to prevent the Novartis subsidiary from launching its version of oral contraceptive Ortho Tri-Cyclen LO until a patent expires in 2019. A spokesman for Novartis said Sandoz had no comment on the lawsuit.
Settling patent infringement issues, Barr Laboratories announced it will provide its generic version of the popular oral contraceptive no later than Dec. 29. The settlement stems from a lawsuit with Ortho Tri-Cyclen's maker, Ortho-McNeil Pharmaceutical.